Kiniksa Pharmaceuticals International plc has provided an update on its ongoing commercial and clinical activities. The company reported approximately $1.5 billion in net revenue since the launch of ARCALYST® (rilonacept), with expected 2026 revenue for the therapy projected at $900 to $920 million. ARCALYST® continues to expand in the recurrent pericarditis market, currently reaching about 18% penetration among patients with multiple recurrences. Kiniksa is advancing its clinical portfolio, including KPL-387, an IL-1 antagonist monoclonal antibody in development for recurrent pericarditis, which has received U.S. Orphan Drug Designation. Phase 2 data for KPL-387 is anticipated in the second half of 2026. Additionally, the company plans to initiate a first-in-human trial of KPL-1161, an Fc-modified IL-1 antagonist monoclonal antibody, by the end of 2026. As of the end of 2025, Kiniksa reported cash reserves of approximately $414 million, supporting its ongoing operations and investment in further development programs. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments